Pharma Pulse 1/7/25: FDA Issues Draft Guidance on AI in Supporting Regulatory Decisions, Strategic AI Budgeting for Pharmacies in 2025 & more

FDA Issues Draft Guidance on the Role of Artificial Intelligence in Supporting Regulatory Decisions

This framework marks the agency’s first official recommendation on the use of AI in drug development.

Strategic AI Budgeting for Pharmacies in 2025

Pharmacies can strategically invest in AI technologies to streamline operations and improve patient care while addressing cost challenges and maximizing return on investment in 2025.

US Surgeon General Calls for Cancer Warnings on Alcohol

Alcoholic drinks like beer and wine should carry warnings of their links to cancer, the US’s top doctor said, citing a lack of public awareness of the popular products’ health risks.

MilliporeSigma Acquires HUB Organoids Holding B.V., Expands Next-Gen Biology Portfolio

The Life Science business of Merck KGaA, Darmstadt, Germany, has acquired HUB Organoids B.V. (HUB), as announced by MilliporeSigma, the US and Canada business of Merck KGaA, Darmstadt, Germany in a December 17 announcement.

The acquisition, which closed on December 23, 2024, is a strategic step aligned with the company’s commitment to providing novel next-generation biology solutions to the life science industry, specifically by enabling wider access to HUB’s technology for faster and more effective drug development. Terms of the deal were not disclosed.

Timothy Marsh and Matt Campasano on LinkedIn

Timothy Marsh: This was a great series and super opportunity to share insights with industry experts Matt Campasano, Bahar Aliakbarian, PhD and Sean O'Hearen. Thanks Nicholas Saraceno!

Matt Campasano: I had fun. Anytime Nicholas Saraceno needs me to blather on about a thing, I’m there.

Have news you want us to share in Pharma Pulse? Reach out to Editor Miranda Schmalfuhs